BACKGROUND: No serum marker is currently available for the diagnosis and treatment of gliomas. Plasminogen activator inhibitor-1 (PAI-1) controls the proteolytic activity in cancer cells and cellular migration during angiogenesis. PATIENTS AND METHODS: To verify the potential of PAI-1 as a serum marker for gliomas, the serum PAI-1 concentrations were measured by ELISA in 57 glioma patients and 34 healthy volunteers. RESULTS: We found significantly higher serum levels in the patients with high-grade gliomas than in the healthy volunteers (p = 0.0009, unpaired t-test) and those with low-grade tumors (p = 0.0074). Furthermore, high-grade glioma patients with a low serum level of PAI-1 survived significantly longer than those with high levels (p = 0.0082). Immunohistochemical analysis using anti-PAI-1 antibody revealed dense and spotty staining in the high-grade tumor tissues from the patients with high serum PAI-1 levels. CONCLUSION: These results suggest that the serum PAI-1 level can be a marker for the prediction of histological grade in intracerebral glioma.
BACKGROUND: No serum marker is currently available for the diagnosis and treatment of gliomas. Plasminogen activator inhibitor-1 (PAI-1) controls the proteolytic activity in cancer cells and cellular migration during angiogenesis. PATIENTS AND METHODS: To verify the potential of PAI-1 as a serum marker for gliomas, the serum PAI-1 concentrations were measured by ELISA in 57 gliomapatients and 34 healthy volunteers. RESULTS: We found significantly higher serum levels in the patients with high-grade gliomas than in the healthy volunteers (p = 0.0009, unpaired t-test) and those with low-grade tumors (p = 0.0074). Furthermore, high-grade gliomapatients with a low serum level of PAI-1 survived significantly longer than those with high levels (p = 0.0082). Immunohistochemical analysis using anti-PAI-1 antibody revealed dense and spotty staining in the high-grade tumor tissues from the patients with high serum PAI-1 levels. CONCLUSION: These results suggest that the serum PAI-1 level can be a marker for the prediction of histological grade in intracerebral glioma.
Authors: Johan M Kros; Dana M Mustafa; Lennard J M Dekker; Peter A E Sillevis Smitt; Theo M Luider; Ping-Pin Zheng Journal: Neuro Oncol Date: 2014-09-24 Impact factor: 12.300
Authors: Ananya Roy; Antoine Coum; Voichita D Marinescu; Jelena Põlajeva; Anja Smits; Sven Nelander; Lene Uhrbom; Bengt Westermark; Karin Forsberg-Nilsson; Fredrik Pontén; Elena Tchougounova Journal: Oncotarget Date: 2015-09-15
Authors: Xiaowen Wang; Matias A Bustos; Xiaoqing Zhang; Romela Irene Ramos; Cong Tan; Yuuki Iida; Shu-Ching Chang; Matthew P Salomon; Kevin Tran; Rebecca Gentry; Yelena Kravtsova-Ivantsiv; Daniel F Kelly; Gordon B Mills; Aaron Ciechanover; Ying Mao; Dave S B Hoon Journal: Cancers (Basel) Date: 2020-04-27 Impact factor: 6.639
Authors: H Taubert; P Würl; T Greither; M Kappler; M Bache; C Lautenschläger; S Füssel; A Meye; A W Eckert; H-J Holzhausen; V Magdolen; M Kotzsch Journal: Br J Cancer Date: 2010-01-05 Impact factor: 7.640